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Abstract
Prenatal factors influence autism spectrum disorder (ASD) incidence in children and can
increase ASD symptoms in offspring of animal models. These may include maternal
immune activation (MIA) due to viral or bacterial infection during the first trimesters. Unfortu-
nately, regardless of ASD etiology, existing drugs are poorly effective against core symp-
toms. For nearly a century a ketogenic diet (KD) has been used to treat seizures, and recent
insights into mechanisms of ASD and a growing recognition that immune/inflammatory con-
ditions exacerbate ASD risk has increased interest in KD as a treatment for ASD. Here we
studied the effects of KD on core ASD symptoms in offspring exposed to MIA. To produce
MIA, pregnant C57Bl/6 mice were injected with the viral mimic polyinosinic-polycytidylic
acid; after weaning offspring were fed KD or control diet for three weeks. Consistent with an
ASD phenotype of a higher incidence in males, control diet-fed MIA male offspring were not
social and exhibited high levels of repetitive self-directed behaviors; female offspring were
unaffected. However, KD feeding partially or completely reversed all MIA-induced behav-
ioral abnormalities in males; it had no effect on behavior in females. KD-induced metabolic
changes of reduced blood glucose and elevated blood ketones were quantified in offspring
of both sexes. Prior work from our laboratory and others demonstrate KDs improve relevant
behaviors in several ASD models, and here we demonstrate clear benefits of KD in the
MIA model of ASD. Together these studies suggest a broad utility for metabolic therapy in
improving core ASD symptoms, and support further research to develop and apply keto-
genic and/or metabolic strategies in patients with ASD.
Introduction
Autism spectrum disorder (ASD) is defined by poor sociability and communication alongside
increased repetitive behaviors or limited behavioral repertoires. Although ASD is defined by
specific behavioral criteria, there is a multitude of genetic and/or environmental contributors,
and most often the etiology is unknown and is likely heterogenous [1]. This inherent complex-
ity and mystery surrounding ASD contributes to and compounds the lack of effective treat-
ments for core behavioral symptoms. Current knowledge suggests environmental factors are
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malleable and sometimes preventable contributors to ASD incidence. Understanding these
factors can aid in addressing ASD prevalence and improving treatment opportunities.
Environmental factors which may be related to increased ASD incidence are diverse, com-
monplace, and some are unavoidable. Some are endogenous factors in the in utero environ-
ment–particularly those associated with inflammation. One common acute inflammatory
event is maternal immune activation (MIA) during the first two trimesters–a physiological
response to infection that increases the risk of persistent autistic behaviors in the offspring [2].
An epidemiological study of over 10,000 ASD cases found that a viral infection in the mother
during the first trimester, and any infection (viral or bacterial) during the second trimester,
was associated with an increased incidence of an ASD diagnosis in the child [3]. Similar find-
ings have been reported in more recent studies [4–6]. MIA-induced inflammation triggers an
increase of proinflammatory factors including interleukins and activates immune cells in the
decidua, bathing the fetus in proinflammatory compounds and antibodies and increasing the
likelihood of the child developing ASD [7]. MIA–induced ASD symptoms have been validated
in multiple animal models: rodent MIA models have been developed using synthetic agents
that induce an immune response such as the RNA mimic polyinosinic-polycytidylic acid (poly
(I:C), evoking an antiviral-type response) and the bacterial cell wall component lipopolysac-
charide (evoking an antibacterial-type response) offspring demonstrate the core symptoms of
autism [8, 9].
The ability for immune/inflammatory conditions to influence ASD incidence has elicited
research into commensurate strategies to prevent or treat ASD. Related to this, low-carbohy-
drate, high-fat ketogenic diets (KDs) have been used for many decades to treat epilepsy,
including epilepsy co-morbid with ASD [10, 11] and there is evidence that they lower inflam-
mation (for instance [12, 13]). Low dietary carbohydrate and limited protein forces nervous
tissue to rely on ketone bodies (acetoacetate, β-hydroxybutyrate, acetone) produced in the
liver for energy. A KD can be effective even in drug-resistant epilepsy [14], with laboratory
and clinical evidence for antiepileptogenesis (e.g. [15, 16]). Studies of chronic and neurodegen-
erative conditions in animal models strongly suggest neuroprotective and disease-modifying
effects of KDs (for example [16, 17]).
Recently there has been growing evidence for the benefits of KDs against core ASD symp-
toms as well as the common ASD comorbidity of epileptic seizures [18]. This includes case
studies in children describing improvements in core symptoms (as well as seizures) [19, 20]
and small pilot studies reporting varied responses including improvements during KD use
[21–23]. More recently, studies have shown that KD treatment improves sociability and
reduces self-directed repetitive behavior in animal models of ASD such as the BTBR T+ tf/J
mouse strain [24], the EL mouse strain [25] and mice with genetic inactivation of the Engrailed
2 gene [26]. Specifically for environmentally-induced ASD, KD feeding improves sociability
and repetitive behavior in the gestational valproic acid model in rats [27, 28]. Here, we admin-
istered prenatal poly(I:C) injections in mice to investigate the effects of maternal inflammation
and subsequent KD treatment on ASD-associated behaviors in male and female offspring.
Materials & methods
Animals
All procedures were performed in accordance with the NIH Guide for the Care and Use of
Laboratory Animals, and approved by the Institutional Animal Care and Use Committee of
Trinity College (A3869–01). Young adult female C57Bl/6 mice (original breeders from Jackson
Laboratories, Bar Harbor, ME) were determined to be proven breeders after having one or two
litters. Proven breeders were housed socially with same-sex cage mates. Estrous cycle was
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monitored daily by visual inspection of the external genitalia [29]. When a breeder was deter-
mined to be in proestrus or estrus, she was housed overnight with an adult male C57Bl/6
mouse. The following morning, the female mouse was checked for the presence of a vaginal
plug, which marked embryonic day 0.5 (E0.5). Pregnant females were housed socially and not
disturbed except for cage cleaning.
On days E10.5, E12.5, and E14.5, dams were weighed and injected intraperitoneally with 5
mg/kg poly(I:C) (potassium salt; P9582; Sigma, St. Louis, MO). Poly(I:C) was supplied by the
manufacturer at 10% of the total weight of the salt; dosage was based on the weight of poly(I:
C) itself. Control dams were not injected to minimize prenatal/gestational stress. Pups from
each litter remained with the mother until postnatal day 21 or 22, when they were weaned and
housed socially with same-sex littermates. Between weaning and 5 weeks of age, all offspring
were fed control diet (CD; LabDiet 5001, W.F. Fisher & Son, Somerville, NJ). At 5 weeks of
age, poly(I:C) littermates were allocated into control and treatment groups and kept on either
CD or switched to KD (F3666; BioServ, Frenchtown, NJ; 6.6:1 fats:(carbohydrates+protein)),
respectively. Fat consisted of lard, butter, and corn oil (47.5%, 20.0%, and 11.4% of total
weight, respectively). Types of fatty acids were saturated (42.6% of fatty acids by weight),
monounsaturated (40.4%), and polyunsaturated (17.1%). Protein was casein. All control group
mice were kept on CD, and testing occurred at 8–9 weeks of age (3–4 weeks of KD treatment).
This age and length of diet treatment is based on our prior work which found beneficial effects
in other ASD models, and the consistent development of ketosis and moderate hypoglycemia
in mice with these parameters [24, 25]. A KD group from control dams was not included as we
have previously found that KD feeding does not significantly affect sociability or grooming in
naïve C57Bl/6 mice [24]. Though it has been proposed that KD treatment in ASD should be
combined with caloric restriction [30], all reports so far have used ad libitum feeding [19–28];
all diets herein were fed ad libitum. At the completion of all testing, mice were euthanized by
isoflurane overdose.
Sociability and communication
Sociability with conspecifics was tested using the three-chamber sociability test, and passive
social communication was tested by social transmission of a food preference [31]. In the three-
chamber sociability test a Plexiglas box divided into three equal chambers was used; a 6 x 6 cm
door in each internal wall allowed for free movement between the chambers. Small cylindrical
wire cages (diameter 10.4 cm, height 11 cm, bar intervals 1 cm) were placed in both side cham-
bers. Test subject mice were first habituated to the testing room for 30 minutes and then habit-
uated to the central chamber for 10 minutes with the doors closed. Testing occurred in three
10 minute phases in which the test mouse was allowed to roam freely between chambers.
The test mouse was placed in the central chamber and the doors were lifted at the start of the
phase. In the first phase, both wire cages were empty, allowing for a test of side bias. In phase
two, a sex and diet-matched "stranger" mouse (C57Bl/6) was placed in the wire cage of one
side chamber, allowing for a test of sociability. In the third phase a novel "stranger" mouse was
placed in the other wire cage to allow for a test of preference for social novelty. Stranger mouse
placement was counterbalanced and stranger mice were fed on the respective experimental
diet for several days before testing to eliminate a possible confound of diet-related olfactory
cues. All activity was video-recorded for later scoring. Sociability in this test was quantified for
1) time spent in each chamber and 2) social contact time (nose/face/forepaw contact with the
cages and/or the stranger mice).
After blood testing of all groups (see below), passive social communication was assessed by
social transmission of a food preference [32]. Mice were habituated to eating KD or powdered
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CD, as appropriate, from glass jars (Dyets, Inc., Bethlehem, PA). Flavors were cocoa (2%) or
cinnamon (1%), with each serving as the trained flavor in half the trials; flavor placement in
the cages was also counterbalanced. All jars were weighed before and after presentation. An
isolated demonstrator mouse was fasted for 18 h, and presented with one jar of powdered fla-
vored food (‘‘trained” flavor) until it had eaten at least 0.5 g. The demonstrator was returned to
the home cage for 30 min to interact with cage-mate observer mice (training). Observer mice
were fasted for 18 h, and then presented simultaneously with both the ‘‘trained” flavor (eaten
by the demonstrator) and an ‘‘untrained” flavor (novel flavored food) for 2 h. In training and
testing, all flavored diets were powdered CD. This maintains a consistent flavored diet scent
during the training and the test. Use of the CD during training and testing is warranted even
in KD-fed mice because during training, when associative learning of the food preference
occurs (or not), the demonstrator mice have eaten the flavor but the observer mice (who are
detecting the flavor) are not eating any food.
Repetitive behavior
To measure self-directed repetitive behavior, self-grooming was quantified in two separate
testing conditions: during the three-chamber sociability test apparatus described above, and
during a separate 10 minute single chamber test. In this latter test, the mouse was habituated
to the room for 30 minutes and then habituated to an experimental polypropylene cage (19 x
29 x 12.5 cm) for 10 minutes. Mouse behavior was video recorded and quantified in a 10 min-
ute phase following habituation.
Blood analysis
One day after the single chamber grooming test, levels of blood glucose and the ketone body β-
hydroxybutyrate were measured. Mice were lightly anesthetized with isoflurane for collection
of tail blood, which was analyzed with Precision Xtra meters (Abbott Laboratories, Bedford,
MA).
Data analysis
As noted, social and grooming behavior videos were scored by two verified and independent
researchers: in all cases at least one was blind to treatment. Sociability preference in the three-
chamber sociability test was defined as the ratio of time spent in the "social" chamber (with a
mouse) to the total time spent in side chambers. Data from each group for each measure were
analyzed with Grubb’s test for outliers, which were eliminated from that particular test, such
that n’s may differ across tests; no mice were outliers for blood glucose or β-hydroxybutyrate.
Statistical analysis was conducted using ANOVA (on ranked data when non-parametric) with
Bonferroni post-hoc tests. Data are reported as mean +/- standard error; p<0.05 was consid-
ered significant. Data are available in S1 File.
Results
Physiology
CD-fed MIA offspring did not differ from control offspring in their blood levels of glucose and
ketones. As expected, KD-fed MIA offspring had the hallmark blood chemistry changes associ-
ated with this metabolic treatment, i.e. ketonemia (measured by increased β-hydroxybutyrate)
and lowered glucose (Fig 1; ketones F = 34.6, p<0.001; glucose F = 10.4, p<0.001). There were
no sex differences in levels of blood glucose or ketones. CD-fed mice gained weight during
diet treatment; KD-fed mice did not change significantly (Fig 1).
Ketogenic diet and maternal immune activation-induced autism
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Sociability
Regarding specific behavioral tests, analysis of chamber times in the three chamber sociability
test revealed that CD-fed male MIA offspring were significantly asocial: in phase 2 of the test
(when a mouse is present) they demonstrated no preference for the side containing the mouse
(Fig 2). In contrast, KD-fed male MIA offspring were significantly social, as were control mice.
With KD treatment the lack of sociability reversed completely–KD-fed male MIA offspring
were not different than control male mice (treatment F = 2.6, p = 0.09; phase F = 15.4, p<0.001;
interaction F = 4.5, p<0.01;). In the phase 3 test of social novelty (when a new mouse is intro-
duced), treatment groups did not differ and all showed a significant preference for social novelty
(Fig 2). Neither MIA nor KD treatment affected chamber time in female mice, which displayed
normal and significantly social behavior (Fig 2; treatment F = 0.2, n.s.; phase F = 9.9, p<0.001;
interaction F = 0.2, n.s.).
Sociability was assessed further by quantifying social contact time in phases of the three
chamber sociability test with mice present (phases 2 and 3). Although MIA did not reduce
social contact significantly in either sex (a trend in males did not reach significance), KD treat-
ment increased social contact in both female and male MIA offspring to levels significantly
above control mice, an effect not seen previously (Fig 2). There were no differences between
phases 2 and 3 (Males: treatment F = 10.4, p<0.001; phase F = 0.2, n.s.; interaction F = 0.9, n.s.
Females: treatment, F = 49.3, p<0.001; phase F = 3.3, n.s.; interaction F = 2.0, n.s.).
We also assessed sociability with a test of passive social communication, the social transmis-
sion of food preference test. However, all treatment groups performed normally and preferred
the trained flavor: males and females were not different, MIA offspring were not impaired, and
this behavior was not modified by KD feeding (Fig 3; H = 1.1, not significant).
Fig 1. Hallmarks of KD therapy confirmed in MIA mice. Left: Blood β-hydroxybutyrate was elevated by KD feeding. Middle: Blood glucose was reduced
by KD feeding. ***p<0.001 compared to CD-fed control offspring; n = 20–23. There were no sex differences in either measure (in initial analysis, sex-by-
treatment interaction: F = 1.7, p = 0.19 for ketones; F = 1.8, p = 0.18 for glucose); male and female data are combined. Right: CD-fed female mice gained
significant weight during diet treatment; KD-fed mice did not. §§§p<0.001 compared to baseline; n = 11–12. Available data from male mice showed a similar
pattern (S1 File).
doi:10.1371/journal.pone.0171643.g001
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Fig 2. KD effects on social behavior in male and female MIA offspring. Top panels: male mice. Top left: Chamber time in
the three-chamber test. CD-fed MIA offspring were not social in phase 2. This effect was reversed by KD feeding. Control
offspring were social, as expected. Mice in all treatment groups showed significant preference for social novelty in phase 3.
Top right: Social contact in the three-chamber test. Social contact time was decreased in male MIA offspring, and elevated by
KD feeding to levels above control offspring. §p<0.05, §§p<0.01, §§§p<0.001 compared to phase 1 within the same treatment
group. *p<0.05 compared to control mice. ###p<0.001 compared to CD-fed MIA offspring; n = 8–12. Bottom panels: female
Ketogenic diet and maternal immune activation-induced autism
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Repetitive behavior
CD-fed male MIA offspring had increased self-directed repetitive behavior as measured by
grooming. The increased grooming was present in the three chamber sociability test in both
non-social (phase 1) and social (phase 2) situations compared to control mice (Fig 4). This ele-
vation was reversed completely by KD feeding such that MIA offspring were no longer differ-
ent from control offspring (treatment F = 48.5, p<0.001; phase F = 62.0, p<0.001; interaction
F = 11.5, p<0.01). CD-fed MIA offspring also had increased self-grooming in the single cham-
ber (non-social) test compared to control offspring (Fig 4); this effect was reversed partially by
KD feeding (F = 22.6, p<0.001). MIA did not elevate grooming in female MIA offspring in
either the three-chamber or single chamber tests (in fact grooming decreased in the social situ-
ation), although KD feeding reduced grooming in female MIA offspring in the three-chamber
test (Fig 4; three-chamber test: treatment F = 6.0, p<0.006; phase F = 32.2; interaction F = 2.5,
n.s.; single-chamber test: F = 0.8, n.s.).
Discussion
The MIA mouse model recapitulates the clinical condition whereby ASD incidence is
increased by a maternal bacterial or viral infection during pregnancy [3–6]. Furthermore,
ASD-associated changes in behavior were selective to male offspring, echoing the high male
mice. Bottom left: Sociability expressed as time in chamber with a mouse was not impaired by MIA treatment and not affected
by KD feeding. §§§p<0.001 overall phase 2 compared to phase 1; n = 10–12. Bottom right: Sociability expressed as social
contact was not impaired by MIA treatment; however KD-feeding elevated social contact. ***p<0.001 overall compared to
CD-fed control and MIA offspring; n = 11 all groups.
doi:10.1371/journal.pone.0171643.g002
Fig 3. Social transmission of food preference. There was no MIA-induced impairment in this task: all
treatment groups learned the social transmission of a safe food flavor; n = 11–13. There were no sex
differences in this behavior (in initial analysis, sex-by-treatment interaction: F = 0.8, p = 0.45).
doi:10.1371/journal.pone.0171643.g003
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Fig 4. Effects of KD on self-directed repetitive grooming behavior. Top panels: male mice. Top left: Self-
directed grooming behavior in the three-chamber test. Grooming was elevated by MIA treatment, and this
effect was reversed completely by KD feeding. Post hoc tests were restricted to within-phase comparisons;
n = 8–10. Top right: Self-directed behavior in the single chamber test. Grooming was elevated by MIA
Ketogenic diet and maternal immune activation-induced autism
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prevalence (4:1 male-to-female) in humans [33]. Here we show that metabolic therapy with a
KD improves and can even reverse ASD-like behaviors in the MIA mouse model.
ASD is associated with poor sociability and communication alongside restricted or repeti-
tive behaviors, and these domains were tested in male and female MIA offspring. Previously,
ASD-like behavioral effects were found in male MIA offspring, and here we also found socia-
bility deficits specific to males [34]. However, three to four weeks of feeding a KD reduced
MIA-induced social abnormalities assessed by the classic three-chamber test of sociability: KD
treatment normalized sociability as assessed by time spent in a side chamber containing a
mouse. In both male and female MIA offspring a KD increased time spent in direct social con-
tact with another mouse during the three-chamber test; in females this increase resulted in
higher social contact time than control animals [34]. Studies using rodent ASD models with
diverse etiologies [strain (mouse: BTBR and EL), genetic (mouse: Engrailed 2 knockout), gesta-
tional exposure (rat: valproic acid)] have also shown elevated sociability after KD feeding in
three-chamber tests [24–26, 28]. In addition, a KD normalizes play behavior in juvenile rats in
the gestational valproic acid model [27]. Regarding another test of sociability, the social trans-
mission of food preference, we found no deficits in the MIA model. Sociability expressed in
this test seems to vary greatly between ASD models [24, 25, 28].
KD treatment also reduced MIA-elevated self-directed repetitive behavior. In the three
chamber test, elevated self-grooming was found in social and non-social phases in males and
solely in the social phase in females. Elevated grooming was also found in the non-social single
chamber test in males but not in females. In all cases repetitive self-grooming was reduced by
KD treatment. In the BTBR mouse model we previously found elevated grooming was limited
to social phases, and, similarly, was decreased and normalized by KD treatment [24]. In the EL
mouse model of comorbid seizures and ASD-like behavior, self-grooming was elevated only in
the non-social phase, yet this was also normalized by KD treatment [25]. Therefore in these
previous studies the KD appeared to revert repetitive behavior to control levels in situations
where they were elevated significantly. Reports with other models have shown similar results:
in the Engrailed 2 genetic model a KD lowered grooming in a social phase, but not a non-social
phase [26]. In the gestational valproic acid model, grooming was measured in unspecified
phase(s) and was reduced by KD treatment [28]. Another type of repetitive behavior, marble
burying, was increased by valproic acid and normalized by KD feeding [28]. Therefore, the
presence of augmented repetitive behaviors seems to depend on social condition and ASD
model. However increased self-grooming is common in these models and KD is beneficial in
reversing increased repetitive behaviors.
As noted, the relevance of the mouse MIA model is due to its clinically-common etiology
and sex-specificity: an increased incidence of ASD is seen after a maternal infection during the
first two trimesters, and the ratio of boys vs. girls diagnosed with ASD is approximately 4:1
[33]. We replicated reliable ASD behaviors in the MIA mouse model, and, like others, found
that only male MIA offspring exhibit reduced sociability and consistently increased self-
directed repetitive behaviors [34]. Preferential effects on males also occur with other classes of
prenatal stressors [35]. The mechanism behind these sex-related differences remains uncer-
tain, although the phenomenon is sufficiently widespread to also occur in birds [36]. In female
MIA offspring sociability was normal and therefore there were no deficits for the dietary
treatment, and this effect was partially reversed by KD feeding. **p<0.01, ***p<0.001 compared to CD-fed
control offspring. ##p<0.01 compared to CD-fed MIA mice; n = 8–10. Bottom panels: female mice. Bottom left:
Grooming in the three-chamber test was not elevated by MIA treatment in females; it was, however, lowered by
KD feeding; n = 11–12. Bottom right: Grooming in the one-chamber test was not affected by MIA or KD in
females. *p<0.05, ***p<0.001 compared to CD-fed control mice.
doi:10.1371/journal.pone.0171643.g004
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treatment to reverse. However, the same KD used in this study augmented sociability and alle-
viated self-directed repetitive behavior significantly in females of the EL mouse strain, a model
of comorbid ASD and epilepsy [25] (KD treatment is also antiepileptogenic against the pro-
gressive seizure phenotype in this strain [37]). Therefore, the KD can exert positive effects on
ASD-like behaviors in both sexes in animal models, and the interaction between sex and the
behavioral effects of KDs might depend on ASD etiology. KD feeding has also been noted to
improve core symptoms in girls with ASD, although the total number of reported female
patients was quite small [20–22]. KD feeding also improves behavior in X chromosome-linked
Rett syndrome, which may be closely related to some forms of ASD [38, 39].
Metabolic benefits of the KD regarding ASD are not solely due to increased fat. Indeed, in
contrast to results obtained here with a KD, a high-fat, sufficient-carbohydrate (i.e. non-keto-
genic) diet worsens ASD core behaviors in the BTBR strain [40]. Thus it is likely that the effects
observed here with KD feeding are due to hallmark metabolic changes such as significant keto-
sis and mildly lowered systemic glucose precipitated by very high fat and restricted carbohy-
drate content. There are also likely a combination of short term and evolving effects of the diet.
Previously we have shown that some behavioral effects required at least one week to evolve,
whereas hallmark metabolic changes in blood chemistry were present within two days [41].
At this time the mechanism(s) whereby metabolic therapy with a KD translates to reduced
core ASD symptoms remain hypothetical; there are many possibilities, and beneficial effects of
the KD are diverse. Key mechanisms may include improved mitochondrial function [42],
reduced inflammation [43], or increased adenosine [44–46]. In various in vitro and in vivo
models, we have shown that a KD increases brain adenosine levels and signaling [16, 47–49];
we have also shown an inverse relationship between adenosine and symptoms of ASD [45].
While the relationship between adenosine and ASD has not been tested directly, abnormalities
in purine metabolism are common in ASD [50–53], and a purinergic treatment has been
shown to be effective in alleviating symptoms [54, 55]. In the gestational valproic acid model,
KD treatment normalized dysfunctions in mitochondrial respiration [27]; mitochondrial dys-
function is common is ASD [56–58]. In the BTBR strain model, KD treatment normalized
abnormal cerebrocortical excitation/inhibition [59], a clinically-relevant aspect of ASD [60].
KD treatment enhanced social novelty-induced neuronal activation in several brain areas of
Engrailed 2 knockout mice–but did not normalize levels of monoamine neurotransmitters
[26]. More research is needed to link metabolic therapy mechanistically to symptoms of ASD.
Because of its long and successful clinical history as a metabolic therapy for epilepsy, much
more work has been done on anticonvulsant mechanisms of KDs. At this time it remains
unclear if anticonvulsant and anti-ASD mechanisms are identical, separate, or mixed, but ASD
and epilepsy are similarly diverse and complicated: in both disorders the specific etiology likely
determines key treatment mechanisms. For this reason it is possible that a broad-acting,
homeostatic treatment–such as a metabolic therapy that engages multiple mechanisms–may
be a particularly beneficial approach. Regardless of mechanism(s), KD improves behavior in
several types of ASD models. The present study demonstrates benefits of a KD in reducing
core ASD symptoms subsequent to MIA, a model with high clinical relevance. Taken together,
emerging findings suggest a wide-ranging utility for metabolic therapies in improving core
ASD symptoms and support further research into mechanisms and applications of these thera-
pies for ASD patients.
Supporting information
S1 File. Data from the study. Different measures are presented on different sheets; treatments
and sex are indicated for all individual subjects. Outliers have been removed, and are marked
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